Target intelligence / Profile preview

Sucrase-isomaltase, intestinal (SI)

Target
SI
Molecular classification
Enzyme, Glycoside hydrolase family 31 (GH31), Disaccharidase
01

Overview

Sucrase-isomaltase, intestinal (SI), is a bifunctional enzyme located in the brush border membrane of enterocytes in the small intestine[1][3][6]. It consists of two subunits, sucrase and isomaltase, both members of the glycoside hydrolase family 31 (GH31), which are responsible for the final step in the digestion of dietary carbohydrates such as sucrose, isomaltose, and maltose into absorbable monosaccharides[1][2][4]. SI is essential for normal carbohydrate absorption and energy production. Mutations in the SI gene can cause congenital sucrase-isomaltase deficiency, leading to malabsorption and gastrointestinal symptoms[3][5]. SI activity can be inhibited by drugs such as acarbose and miglitol, which are used to slow glucose absorption in diabetes management. Interaction with another enzyme, maltase-glucoamylase, influences carbohydrate digestion efficiency and disease phenotypes in GI syndromes[5][1].

Other names
Sucrase-isomaltaseSIsucrase alpha-glucosidaseisomaltase (component of the complex)intestinal sucrasedisaccharidase
02

Mechanism of action

Alpha-glucosidase inhibition (inhibitors reduce enzymatic hydrolysis of disaccharides, slowing glucose absorption)

03

Biological functions

Carbohydrate digestionHydrolysis of dietary disaccharides (sucrose, isomaltose, maltose)Energy production via monomer release for absorption
04

Disease associations

Congenital sucrase-isomaltase deficiencyCarbohydrate malabsorption syndromes (e.g., contributing to irritable bowel syndrome)Gastrointestinal disorders (general category – “Other”)
05

Safety considerations

Deficiency can lead to gastrointestinal symptoms (diarrhea, pain, bloating, malabsorption)Drug inhibition can cause carbohydrate malabsorption and GI side-effects
06

Interacting drugs

Miglitol

2 more in the full profile.

07

Biomarkers

Decreased SI activity or deficiency in genetic testing for congenital sucrase-isomaltase deficiencyMeasurement of fecal carbohydrate for functional diagnosis

Beyond the preview

Go deeper on Sucrase-isomaltase, intestinal (SI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sucrase-isomaltase, intestinal (SI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call